Analysis of potentially predictive factors of efficacy of adjunct extended-release quetiapine fumarate in patients with major depressive disorder
| Autor: | Michael Bauer, Michael E. Thase, Sherry Liu, Willie Earley, Hans Eriksson |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.drug_class Population Atypical antipsychotic Placebo Severity of Illness Index Quetiapine Fumarate Young Adult Double-Blind Method Internal medicine Severity of illness medicine Humans Zusatz atypisches Antipsychotikum Quetiapin-Fumarat mit verlängerter Freisetzung schwere depressive Störung prädiktive Faktoren Pharmacology (medical) ddc:610 Psychiatry education Aged Psychiatric Status Rating Scales Pharmacology Depressive Disorder Major education.field_of_study Middle Aged medicine.disease Antidepressive Agents Psychiatry and Mental health Treatment Outcome Delayed-Action Preparations Montgomery–Åsberg Depression Rating Scale Quetiapine Major depressive disorder Drug Therapy Combination Female Psychology Adjunct atypical antipsychotic extended-release quetiapine fumarate major depressive disorder predictive factors Antipsychotic Agents medicine.drug |
| Zdroj: | Journal of Psychopharmacology. 29:565-574 |
| ISSN: | 1461-7285 0269-8811 |
| DOI: | 10.1177/0269881114552715 |
| Popis: | Identification of predictors of treatment response in patients with major depressive disorder (MDD) may facilitate improved disease management. Data were pooled from two 6-week, double-blind, placebo-controlled studies of extended-release quetiapine (quetiapine XR; 150 or 300 mg/day) as adjunct to ongoing antidepressant therapy. Effects of psychiatric history and baseline demographic and disease characteristics on efficacy outcomes (Week 6 Montgomery Åsberg Depression Rating Scale [MADRS] total score reduction) were evaluated in population subgroups (quetiapine XR both doses pooled, n = 616; placebo, n = 303). Baseline Clinical Global Impressions-Severity (CGI-S) score and previous depressive episodes on Week 6 MADRS total score change, and baseline MADRS individual item scores on Week 6 change in CGI-Improvement score, were also evaluated. No major differences between responders and non-responders to quetiapine XR were observed for patient characteristics or demographic and disease characteristics. No suggestion of a predictive association was found between baseline CGI-S score, number of depressive episodes, and baseline MADRS item scores and efficacy outcomes. These analyses showed no major differences between responders and non-responders, and no predictive association between the parameters assessed and efficacy outcomes for adjunct quetiapine XR in patients with MDD and an inadequate response to prior antidepressant therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|